These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 18829747)
1. Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. Grove J; Nielsen S; Zhong J; Bassendine MF; Drummer HE; Balfe P; McKeating JA J Virol; 2008 Dec; 82(24):12020-9. PubMed ID: 18829747 [TBL] [Abstract][Full Text] [Related]
2. Role of Conserved E2 Residue W420 in Receptor Binding and Hepatitis C Virus Infection. Cowton VM; Angus AGN; Cole SJ; Markopoulou CK; Owsianka A; Dunlop JI; Gardner DE; Krey T; Patel AH J Virol; 2016 Aug; 90(16):7456-7468. PubMed ID: 27279607 [TBL] [Abstract][Full Text] [Related]
3. Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. Grove J; Huby T; Stamataki Z; Vanwolleghem T; Meuleman P; Farquhar M; Schwarz A; Moreau M; Owen JS; Leroux-Roels G; Balfe P; McKeating JA J Virol; 2007 Apr; 81(7):3162-9. PubMed ID: 17215280 [TBL] [Abstract][Full Text] [Related]
4. Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors. Lavie M; Sarrazin S; Montserret R; Descamps V; Baumert TF; Duverlie G; Séron K; Penin F; Dubuisson J J Virol; 2014 Sep; 88(18):10584-97. PubMed ID: 24990994 [TBL] [Abstract][Full Text] [Related]
5. A Library of Infectious Hepatitis C Viruses with Engineered Mutations in the E2 Gene Reveals Growth-Adaptive Mutations That Modulate Interactions with Scavenger Receptor Class B Type I. Zuiani A; Chen K; Schwarz MC; White JP; Luca VC; Fremont DH; Wang D; Evans MJ; Diamond MS J Virol; 2016 Dec; 90(23):10499-10512. PubMed ID: 27630236 [TBL] [Abstract][Full Text] [Related]
6. Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors. Bitzegeio J; Bankwitz D; Hueging K; Haid S; Brohm C; Zeisel MB; Herrmann E; Iken M; Ott M; Baumert TF; Pietschmann T PLoS Pathog; 2010 Jul; 6(7):e1000978. PubMed ID: 20617177 [TBL] [Abstract][Full Text] [Related]
7. Role of hypervariable region 1 for the interplay of hepatitis C virus with entry factors and lipoproteins. Bankwitz D; Vieyres G; Hueging K; Bitzegeio J; Doepke M; Chhatwal P; Haid S; Catanese MT; Zeisel MB; Nicosia A; Baumert TF; Kaderali L; Pietschmann T J Virol; 2014 Nov; 88(21):12644-55. PubMed ID: 25142595 [TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus protects human B lymphocytes from Fas-mediated apoptosis via E2-CD81 engagement. Chen Z; Zhu Y; Ren Y; Tong Y; Hua X; Zhu F; Huang L; Liu Y; Luo Y; Lu W; Zhao P; Qi Z PLoS One; 2011 Apr; 6(4):e18933. PubMed ID: 21526201 [TBL] [Abstract][Full Text] [Related]
9. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. Bartosch B; Vitelli A; Granier C; Goujon C; Dubuisson J; Pascale S; Scarselli E; Cortese R; Nicosia A; Cosset FL J Biol Chem; 2003 Oct; 278(43):41624-30. PubMed ID: 12913001 [TBL] [Abstract][Full Text] [Related]
10. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity. Keck ZY; Li SH; Xia J; von Hahn T; Balfe P; McKeating JA; Witteveldt J; Patel AH; Alter H; Rice CM; Foung SK J Virol; 2009 Jun; 83(12):6149-60. PubMed ID: 19321602 [TBL] [Abstract][Full Text] [Related]
11. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. Dreux M; Pietschmann T; Granier C; Voisset C; Ricard-Blum S; Mangeot PE; Keck Z; Foung S; Vu-Dac N; Dubuisson J; Bartenschlager R; Lavillette D; Cosset FL J Biol Chem; 2006 Jul; 281(27):18285-95. PubMed ID: 16675450 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Krieger SE; Zeisel MB; Davis C; Thumann C; Harris HJ; Schnober EK; Mee C; Soulier E; Royer C; Lambotin M; Grunert F; Dao Thi VL; Dreux M; Cosset FL; McKeating JA; Schuster C; Baumert TF Hepatology; 2010 Apr; 51(4):1144-57. PubMed ID: 20069648 [TBL] [Abstract][Full Text] [Related]
13. Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion. Haberstroh A; Schnober EK; Zeisel MB; Carolla P; Barth H; Blum HE; Cosset FL; Koutsoudakis G; Bartenschlager R; Union A; Depla E; Owsianka A; Patel AH; Schuster C; Stoll-Keller F; Doffoël M; Dreux M; Baumert TF Gastroenterology; 2008 Nov; 135(5):1719-1728.e1. PubMed ID: 18718838 [TBL] [Abstract][Full Text] [Related]
14. Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission. Catanese MT; Loureiro J; Jones CT; Dorner M; von Hahn T; Rice CM J Virol; 2013 Aug; 87(15):8282-93. PubMed ID: 23698298 [TBL] [Abstract][Full Text] [Related]
15. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1. Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563 [TBL] [Abstract][Full Text] [Related]
16. Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps. Dao Thi VL; Granier C; Zeisel MB; Guérin M; Mancip J; Granio O; Penin F; Lavillette D; Bartenschlager R; Baumert TF; Cosset FL; Dreux M J Biol Chem; 2012 Sep; 287(37):31242-57. PubMed ID: 22767607 [TBL] [Abstract][Full Text] [Related]
17. Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains. Dreux M; Dao Thi VL; Fresquet J; Guérin M; Julia Z; Verney G; Durantel D; Zoulim F; Lavillette D; Cosset FL; Bartosch B PLoS Pathog; 2009 Feb; 5(2):e1000310. PubMed ID: 19229312 [TBL] [Abstract][Full Text] [Related]
18. Interplay between basic residues of hepatitis C virus glycoprotein E2 with viral receptors, neutralizing antibodies and lipoproteins. Koutsoudakis G; Dragun J; Pérez-Del-Pulgar S; Coto-Llerena M; Mensa L; Crespo G; González P; Navasa M; Forns X PLoS One; 2012; 7(12):e52651. PubMed ID: 23300734 [TBL] [Abstract][Full Text] [Related]
19. Tupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection. Tong Y; Zhu Y; Xia X; Liu Y; Feng Y; Hua X; Chen Z; Ding H; Gao L; Wang Y; Feitelson MA; Zhao P; Qi ZT J Virol; 2011 Mar; 85(6):2793-802. PubMed ID: 21177818 [TBL] [Abstract][Full Text] [Related]
20. Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor. Wünschmann S; Medh JD; Klinzmann D; Schmidt WN; Stapleton JT J Virol; 2000 Nov; 74(21):10055-62. PubMed ID: 11024134 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]